Clinical Development, Nurses and Pharmacokinetics

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Development

Nurses

Pharmacokinetics

BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with DeliriumFifth potential indication for BXCL501, an orally dissolving thin film

The Pharma Data

OCTOBER 25, 2020

In addition, this indication offers synergy with the commercial infrastructure being developed to support our first New Drug Application.”. The most commonly used and recommended instrument for agitation assessment in the ICU is the Richmond Agitation-Sedation Scale (“RASS”).

Treatment

Treatment Trials FDA Hospitals

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

The Pharma Data

APRIL 8, 2021

Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA. The full range of data from Roche’s clinical development programme in neuroscience being presented at 2021 AAN include: Medicine and/or Therapeutic Area.

Clinical Trials

Clinical Trials Trials Disease Therapies

Drug Discovery Digest

BioXcel Therapeutics Receives FDA Clearance of IND for Phase 2 Trial with BXCL501 for the Treatment of Agitation Associated with DeliriumFifth potential indication for BXCL501, an orally dissolving thin film

2021 AAN highlight impact and breadth of expanding neuroscience portfolio

Stay Connected